46. 悪性関節リウマチ Malignant rheumatoid arthritis Clinical trials / Disease details
臨床試験数 : 4,325 / 薬物数 : 2,671 - (DrugBank : 417) / 標的遺伝子数 : 187 - 標的パスウェイ数 : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04196868 (ClinicalTrials.gov) | December 3, 2020 | 5/12/2019 | Methotrexate and Metformin in Rheumatoid Arthritis Patients | Randomized Placebo-controlled Trial Comparing Methotrexate vs. Methotrexate/Metformin Association in Rheumatoid Arthritis Patients | Arthritis, Rheumatoid | Drug: Metformin treatment;Other: Placebo;Drug: Methotrexate treatment | University Hospital, Bordeaux | Ministry for Health and Solidarity, France | Recruiting | 18 Years | N/A | All | 128 | Phase 2 | France |
| 2 | EUCTR2018-004287-56-FR (EUCTR) | 21/11/2019 | 31/01/2020 | Methotrexate and Metformin in rheumatoid arthritis patients | Randomized placebo-controlled trial comparing Methotrexate vs. Methotrexate/Metformin association in rheumatoid arthritis patients: METorMET² study - METorMET2 | rheumatoid arthritis (RA) MedDRA version: 20.0;Level: HLT;Classification code 10039075;Term: Rheumatoid arthritis and associated conditions;System Organ Class: 100000004870 ;Therapeutic area: Body processes [G] - Immune system processes [G12] | Trade Name: METFORMINE ARROW 500mg Product Name: Metformin Trade Name: Methotrexate Product Name: Methotrexate Trade Name: Methotrexate Product Name: Methotrexate Trade Name: Acide folique Product Name: Acide folique Product Code: B03BB01 Trade Name: Prednisone Product Name: Prednisone Product Code: H02AB07 | CHU de Bordeaux | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 128 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | France | ||
| 3 | NCT04068246 (ClinicalTrials.gov) | August 1, 2019 | 21/8/2019 | The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients | The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial. | Rheumatoid Arthritis | Drug: Metformin;Drug: Placebo | Sadat City University | NULL | Completed | 18 Years | N/A | All | 120 | Phase 1/Phase 2 | Egypt |
| 4 | NCT03863405 (ClinicalTrials.gov) | January 9, 2019 | 4/3/2019 | Metformin Use in Rheumatoid Arthritis | The Effect of Metformin on the Clinical Outcome of Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Metformin;Drug: Conventional DMARDs;Drug: Placebo Oral Tablet | Ain Shams University | Future University in Egypt | Recruiting | 18 Years | N/A | All | 60 | Phase 2 | Egypt |
| 5 | ChiCTR-INR-17011772 | 2017-06-27 | 2017-06-28 | Canceled by the investigator The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agents | The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agents | Rheumatoid Arthritis | test group:Metformin tablets, 0.25g, 3 / day, oral, atorvastatin tablets 10mg, 1 / night, oral;;Control group:Traditional DMARDs group; | Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated Hospital | NULL | Recruiting | 18 | 65 | Both | test group:80;Control group:40; | China | |
| 6 | ChiCTR-IPR-17010325 | 2017-01-31 | 2017-01-04 | The efficacy and safety of Metformin combined with coenzyme Q10 in refractory rheumatoid arthritis: A multi-center randomized controlled trial | The efficacy and safety of Metformin combined with coenzyme Q10 in refractory rheumatoid arthritis: A multi-center randomized controlled trial | rheumatic disease;M05.901 | Metformin Group:Metformin combined Glucocorticoids and DMARDs;Non-Metformin Group:Glucocorticoids and DMARDs;Metformin combined with Coenzyme Q10 Group:Metformin and Coenzyme Q10 combined Glucocorticoids and DMARDs; | the Second Hospital of Shanxi Medical University | NULL | Pending | 18 | 65 | Both | Metformin Group:100;Non-Metformin Group:100;Metformin combined with Coenzyme Q10 Group:100; | China | |
| 7 | NCT02246257 (ClinicalTrials.gov) | September 2014 | 17/9/2014 | Early Rheumatoid Arthritis COR Intervention | Multifactorial Intervention to Prevent Cardiovascular Disease in Patients With Early Rheumatoid Arthritis | Rheumatoid Arthritis;Cardiovascular Diseases | Other: Simvastatin;Other: Losartan;Other: Metformin;Other: Outpatient rheumatology department;Other: Refered to general practice | MD, PhD, Annemarie Lyng Svensson | NULL | Recruiting | 18 Years | N/A | All | 300 | N/A | Denmark |
| 8 | NCT01405118 (ClinicalTrials.gov) | June 2011 | 7/7/2011 | Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers | A Phase 1, Open Labeled, Fixed Sequence Study To Estimate The Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy Volunteers | Rheumatoid Arthritis | Drug: Metformin/CP-690,550 | Pfizer | NULL | Completed | 18 Years | 55 Years | Both | 24 | Phase 1 | Belgium |
| 9 | EUCTR2008-005708-18-GB (EUCTR) | 04/06/2010 | 14/04/2010 | Prevention of metabolic complications of glucocorticoid excess - Prevention of metabolic complications of glucocorticoid excess | Prevention of metabolic complications of glucocorticoid excess - Prevention of metabolic complications of glucocorticoid excess | Rheumatoid arthritis, SLE, Polymyalgia rheumatica, Disthyroid eye disease, Cushing's syndrome | Trade Name: Glucophage (metformin) Product Name: Metformin | Queen Mary University of London | NULL | Not Recruiting | Female: yes Male: yes | 100 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | United Kingdom |